Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 May 15;22(5):594-595.
doi: 10.1093/neuonc/noaa055.

A troublesome burden, the amplification of EGFR in glioblastoma!

Mina Lobbous  1 , L Burt Nabors  1
Affiliations
Editorial

A troublesome burden, the amplification of EGFR in glioblastoma!

Mina Lobbous et al. Neuro Oncol. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. van den Bent MJ, Eoli M, Sepulveda JM. INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. Neuro Oncol. 2019; doi: 10.1093/neuonc/noz222. - DOI - PMC - PubMed
    1. Trivedi RN, Almeida KH, Fornsaglio JL, Schamus S, Sobol RW. The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death. Cancer Res. 2005;65(14):6394. - PubMed
    1. Touat M, Idbaih A, Sanson M, Ligon KL. Glioblastoma targeted therapy: updated approaches from recent biological insights. Ann Oncol. 2017;28(7):1457–1472. - PMC - PubMed
    1. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. New Engl J Med. 2005;353(19):2012–2024. - PubMed
    1. van den Bent MJ, Gao Y, Kerkhof M, et al. Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas. Neuro Oncol. 2015;17(7):935–941. - PMC - PubMed